Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional …
Introduction Women with breast cancer who do not adhere to adjuvant endocrine therapy
(AET) have increased risks of mortality and recurrence. There are multiple barriers to AET …
(AET) have increased risks of mortality and recurrence. There are multiple barriers to AET …
Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping …
Background Adjuvant endocrine therapy (AET) reduces the risk of breast cancer recurrence
and mortality. However, up to three-quarters of women with breast cancer do not take AET …
and mortality. However, up to three-quarters of women with breast cancer do not take AET …
Oral anticancer therapies: addressing nonadherence in patients with breast cancer
M Cazzaniga, J Huober, A Tamma, A Emde… - Clinical Breast …, 2024 - Elsevier
Purpose This review aims to investigate the issue of treatment nonadherence and to present
the available strategies to improve adherence to oral treatments in breast cancer. Methods A …
the available strategies to improve adherence to oral treatments in breast cancer. Methods A …
Supporting endocrine therapy adherence in women with breast cancer: findings from the ROSETA pilot fractional factorial randomized trial
SG Smith, SMC Green, E McNaught… - Annals of Behavioral …, 2025 - academic.oup.com
Background Adherence to adjuvant endocrine therapy (AET) in women with breast cancer is
poor. Multicomponent intervention packages are needed to address adherence barriers …
poor. Multicomponent intervention packages are needed to address adherence barriers …
Motivational interviewing counseling to increase endocrine therapy adherence in diverse patients
SB Wheeler, J Spencer, SW Drier, N Fray… - Cancers, 2023 - mdpi.com
Simple Summary Up to ten years of oral endocrine therapy can help prevent breast cancer
recurrence and death in approximately 70% of patients diagnosed with hormone-receptor …
recurrence and death in approximately 70% of patients diagnosed with hormone-receptor …
A pilot randomised controlled trial of acceptance and commitment therapy for medication decision‐making and quality of life in women with breast cancer: The …
CD Graham, R Ellison, LH Hall, J Clark… - Psycho …, 2024 - Wiley Online Library
Objective Non‐adherence to adjuvant endocrine therapy (AET) in women with breast cancer
is common and associated with medication side‐effects and distress. We co‐designed an A …
is common and associated with medication side‐effects and distress. We co‐designed an A …
Assessing multidimensional fidelity in a pilot optimization trial: A process evaluation of four intervention components supporting medication adherence in women with …
Adherence to adjuvant endocrine therapy in women with breast cancer is low. We
conducted a 24-1 fractional factorial pilot optimization trial to test four intervention …
conducted a 24-1 fractional factorial pilot optimization trial to test four intervention …
The ethanolic extract of Aframomum angustifolium seeds protects against tamoxifen-induced side effects in rats with breast cancer
I Makamwe, FR Ntentie, MAA Mbong… - Advances in Traditional …, 2024 - Springer
Long-term use of tamoxifen (TAM) is associated with severe side effects. The present study
aimed at evaluating the protective effect of the ethanolic extract of Aframomum angustifolium …
aimed at evaluating the protective effect of the ethanolic extract of Aframomum angustifolium …
乳腺癌患者内分泌治疗阶段药物相关症状管理的证据总结
张晓萌， 王悦， 万巧琴 - 中国癌症防治杂志, 2024 - zgazfz.com
目的总结乳腺癌患者在内分泌治疗阶段药物相关症状管理的最佳证据, 为临床实践提供循证依据
. 方法遵循循证“6S” 证据模型, 使用计算机对BMJ 最佳临床实践, Up To Date …
. 方法遵循循证“6S” 证据模型, 使用计算机对BMJ 最佳临床实践, Up To Date …
[HTML][HTML] Protocol: Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for …
Introduction Women with breast cancer who do not adhere to adjuvant endocrine therapy
(AET) have increased risks of mortality and recurrence. There are multiple barriers to AET …
(AET) have increased risks of mortality and recurrence. There are multiple barriers to AET …